Results
Mar 10 2010
Cellzome Announces Second Major Strategic Drug Discovery Alliance with GlaxoSmithKline in Inflammatory Disease
Feb 24 2010
Dom Vidal - The Sunday Interview in The Telegraph
Jan 28 2010
Marten Mickos joins Index as European Entrepreneur-in-Residence
Jan 25 2010
Mimecast secures £13 million in Series B funding from leading investors
Jan 19 2010
Boku raises $25 million in series C funding
Dec 15 2009
Molecular Partners Secures CHF 46 million in Series B Financing
Nov 12 2009
PanGenetics announces acquisition by Abbott of PG110 anti-NGF antibody to treat chronic pain.
Nov 09 2009
Electronic Arts Acquires Playfish
Nov 09 2009
Index and Accel Announce Exit of Playfish to Electronic Arts
Oct 22 2009
Jesper Balser joins Milestone Board of Directors
Cellzome Announces Second Major Strategic Drug Discovery Alliance with GlaxoSmithKline in Inflammatory Disease
March 10 2010
Cellzome today announced that it has formed a second strategic alliance with GlaxoSmithKline (GSK). This new collaboration gives GSK exclusive access to Cellzome's proprietary EpisphereTM technology in the emerging field of epigenetics as applied to immunoinflammatory disease. Epigenetic mechanisms play a key role in controlling immune cell differentiation and inflammatory gene expression during an excessive inflammatory response.Under the terms of the agreement, the companies will work together using Cellzome's EpisphereTM technology platform, to identify selective small-molecule drug candidates against targets from four different epigenetic target classes. The companies will share operational responsibility for the programs until identification of drug candidates, at which stage GSK will assume responsibility for any further preclinical and clinical development and commercialisation.
Under the financial terms, Cellzome will receive an upfront payment of €33 million, comprising technology access fees and the purchase of equity. In addition, Cellzome is eligible for milestone payments and tiered royalties for each programme. Milestone payments under this collaboration could reach over €475 million if all programmes under the alliance are successfully developed and commercialised.
Tim Edwards, Chief Executive Officer of Cellzome, said: "We are delighted to form another major alliance with GSK, using our leading technology and people to find transformative medicines in this exciting field of biology. Combining forces with GSK will accelerate the development of new anti-inflammatory drugs for the benefit of patients."
Back to top
